Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Allogeneic Stem Cell Transplant with Non-Myeloablative Conditioning


An allogeneic stem cell transplantation with non-myeloablative conditioning is currently an option which is still experimental. The method and indication is therefore under constant change.


  • Patient is not appropriate for a conventional allogeneic stem cell transplantation (age, complicated illness, < 70 years).
  • The disease is potentially curable with an allogeneic stem cell transplantation.
  • No CNS involvement from the disease. 
  • Left ventricle ejection fraction ≥ 40 %.
  • No serious disturbances in lung function (need for oxygen supply, DLCO < 30 %, FEV1 < 30%).
  • No serious disturbances of biochemical liver parameters, that is:
    • bilirubin more than 2 fold above the normal limit 
    • ASAT and ALAT more than 4 fold above the normal limit
  • Karnofsky score greater than or equal to 50%.
  • Blood pressure 150/90 with standard hypertension medication.
  • Renal function almost normal.

The principle for this type of treatment is to utilize the anti-tumor effect from the donor's T-lymphocytes (and NK cells). The mechanism for this effect is unclear and the frequency of response varies from disease to disease. The method consists of a conditioning regimen which is strongly immunosuppressive, but not myeloablative, to achieve a mixed and subsequent full T-cell chimerism. When the result is successful, the autologous tumor cells are destroyed by the allogeneic lymphocytes. 


  • Patients with an HLA-identical relative donor or 10/10 identical unrelated donor, who are not suitable for conventional allogeneic stem cell transplantation. Preferably within diagnosis-specific clinical protocols. Must be reported to EBMT.

Possible diagnoses: 

  • Mantel cell- and follicular lymphoma with recurrence after HMAS and chemosensitive disease
  • Chronic lymphocytic leukemia after unsuccessful chemotherapy, including fludarabine
  • Chronic myeloid leukemia with unsuccessful cytogenetic response to optimal drug therapy
  • Multiple myeloma after HMAS
  • AML in research protocol - patients with potential family donor


  • Cure the disease.

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2018